Gormonoterapiya metatstaticheskogo i retsidivnogo raka endometriya


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In economically developed countries, at least 30% of the patients with endometrial cancer (EC) die during the 5-year follow-up that determines the relevance of the treatment of these forms of the disease. Pronounced hormonal dependence is a distinctive feature of the EC. The article analyzes in detail the mechanisms of the pathogenesis of EC on the basis of a comparison of clinical, morphological and endocrinological data. The most common methods of treatment are described. The article presents the evidence that hormonal therapy is an effective palliative treatment of metastatic and recurrent EC, and promising field of clinical and experimental medicine.

Full Text

Restricted Access

About the authors

E. V Bakhidze

Email: bakhidze@yandex.ru

References

  1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, et al. Endometrial cancer. Lancet 2005;366:491-505.
  2. Мерабишвили В.М. Злокачественные новообразования в мире, России, Санкт-Петербурге. СПб., 2007. 424 с.
  3. Howlader N, Noone AM, Krapcho M et al. Edwards BK (eds). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/ csr/1975_2008
  4. Мерабишвили В.М. Выживаемость онкологических больных. СПб., 2006, 440 с.
  5. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205-12.
  6. Gusberg SB. Estrogen and endometrial cancer: an epilogue a la гє^єг^й du temps perdu. Gynecol Oncol 1994;52(1):301-509.
  7. Берштейн Л.М. Гормональный канцерогенез. СПб., 2000. 199 с.
  8. Pike MC, Spicer DV. The Prevention of Femal Cancers in the Accomplistments in cancer Research. Philadelphia: J.B. Lippincot Company, 1992:115-39.
  9. Бохман Я.В. Рак тела матки. Кишенев-Штиинца, 1972, 218 с.
  10. Берштейн Л.М. Эпидемиология, патогенез и пути профилактики рака эндометрия: стабильность или эволюциия// Практическая онкология 2004. Т. 5. С. 1-8.
  11. Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol. 2007;46(1):26-32.
  12. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 1997;81:228-32.
  13. Longy M. Cowden disease and the PTEN gene: a successfully clinical and biological combined approach. Bull Cancer 2001;88(12):1153-58.
  14. Creasman WT, Soper JT, Kenneth S, et al. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 1985;151:922-32.
  15. Chambers JT. Sex Steroid Receptors in Endometrial Cancer. Yale J Biol Med 1988;61:339-50.
  16. Lindahl В, et al. Correlation between estradiol-17 beta and progesterone cytosol receptor concentration, histologic differentiation and 3 H-thymidine incorporation in endometrial carcinoma. Anticancer Res 1982;2(4):203-07.
  17. Цырлина E.D., Софроний Д.Ф., Дильман В.М., Бохман Я.В. и др. Влияние тамоксифена на содержание цитоплазматических рецепторов стероидных гормонов в опухоли у больных раком тела матки // Вопр. онкол. 1989. № 35(6). С. 675-80.
  18. Utaaker E, Iversen OE, Skaarland E. The distribution and prognostic implications of steroid receptors in endometrial carcinomas. Gynecol Oncol 1987;28:89-100.
  19. Hunter RE, Longcope C, Jordan VC. Steroid hormone receptors in adenocarcinoma of the endometrium. Gynecol Oncol 1980;10:152-61.
  20. Вишневский А.С., Бохман Я.В., Цырлина Е.В. и др. Влияние прогестинотерапии на уровень цитоплазматических рецепторов у больных раком тела матки // Вопр. онкол. 1989;35(5):594-98.
  21. Бохман Я.В., Бонтэ Я., Вишневский А.С. и др. Гормонотерапия рака эндометрия. СПб., 1992. 157 с.
  22. Бахидзе Е.В. Фертильность, беременность и гинекологический рак. СПб., 2004. 288 с.
  23. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
  24. Alexander IF, Shine J, Sutherland RL. Progestin regulation of estrogen receptor messenger RNA in human breast cancer cells. Mol Endocrinol 1990;4:821-28.
  25. Kashima H, Horiuchi A, Uchikawa J, et al. Up-regulation of nuclear receptor corepressor (NCoR) in progestin-induced growth suppression of endometrial hyperplasia and carcinoma. Anticancer Res 2009;29:1023-29.
  26. Miyamoto T, Horiuchi A, Kashima H, et al. Inverse correlation between Skp2 andp27(Kip1) in normal endometrium and endometrial carcinoma. Gynecol Endocrinol 2010;26:220-29.
  27. Kelley RM. In Proceeding of the Second Conference in Steroids and Cancer. Chicago, American Medical Associates, 1951:116.
  28. Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961;264.
  29. Thigpen T, Blessing J, DiSaia P, et al. Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: Results of therapy and correlation with estrogen and progesterone receptor levels - The Gynecologic Oncology Group experience, in Baulier E, Iacobelli S, McGuire W (eds): Endocrinology and Malignancy. Pearl River, NY, Parthenon Publishers, 1986:446-54.
  30. Yang S, Thiel KW, De Geest K, Leslie KK. Endometrial cancer: reviving progesterone therapy in the molecular age. Discov Med 2011;12(64):205-12.
  31. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007;17(5):964-78.
  32. Kauppila A, Vihko R. Estrogen and progestin receptors as prognosis markers in endometrial cancer. In: Schultz KD, et al. Endometrial cancer, 1987:104-11.
  33. Markman M. Hormonal therapy of endometrial cancer. Eur J Cancer 2005;41(5):673-75.
  34. Mortel R, Zaino R, Satyaswaroop PG. Heterogeneity and progesterone-receptor distribution in endometrial adenocarcinoma. Cancer1984;53(1):113-16.
  35. Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 2000;97(3):1032-37.
  36. Bonte J. The endometrial adenocarcinoma as a model for hormone-dependency and hormone-responsiveness of gynaecological cancers. Eur J Obstet Gynecol Reprod Biol 1984;18(5-6):335-41.
  37. Carlson JA, Jr, Allegra JC, Day TG, Jr, Wittliff JL. Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia. Am J Obstet Gynecol 1984;149(2):149-53.
  38. Цырлина Е.В., Софроний Д.Ф., Дильман В. М., Бохман Я.В., Вишневский А.С., 3ельдович Д.Р. Влияние тамоксифена на содержание цитоплазматических рецепторов стероидных гормонов в опухоли у больных раком тела матки//Вопр. онкол. 1989. Т. 35. С. 675-79.
  39. Bakhidze EV, Bokhman JaV. Application of thymic factor «Thymalin» in complex treatment of endometrial cancer patients. Eur J Gynaecol Oncol 1990;11(4):251-56.
  40. Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, Lee RB. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92(1):4-9.
  41. Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92(1):10-4.
  42. Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK, Schinella RA, Davis TE. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol 2001;24(1):43-6.
  43. Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Stud. Gynecol Oncol 2007; 106(2):325-33.
  44. Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab 2011;22(4):145-52.
  45. Balch C, Matei DE, Huang TH-M, Nephew KP. Role of epigenomics in ovarian and endometrial cancers// Epigenomics. 2010; 2(3):419-47.
  46. Emons G, Schroder B, Ortmann O, et al. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 1993; 77:1458.
  47. Covens A, Thomas G, Shaw P, et al. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol.Oncol 1997; 64:126-29.
  48. Lhomme C, Vennin P, Callet N, et al. Amulticenter phase II study with triptorelin (sustained release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study. Gynecol Oncol1999;75: 187-93.
  49. Umene K, Banno R, Kisu I, et al. New candidate therapeutic agents for endometrial cancer: Potential for clinical practice (Review). Oncology reports 2013;29:855-60.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies